Manulife (Manufacturers Life Insurance)
SYRE icon

Manulife (Manufacturers Life Insurance)’s Spyre Therapeutics SYRE Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.28M Sell
104,516
-8,325
-7% -$607K 0.01% 925
2026
Q1 		$5.69M Sell
112,841
-16,172
-13% -$610K ﹤0.01% 1102
2025
Q4 		$4.14M Buy
129,013
+57,065
+79% +$1.49M ﹤0.01% 1250
2025
Q3 		$1.21M Sell
71,948
-7,948
-10% -$130K ﹤0.01% 1757
2025
Q2 		$1.2M Buy
79,896
+25,995
+48% +$385K ﹤0.01% 1736
2025
Q1 		$870K Buy
53,901
+1,139
+2% +$23.7K ﹤0.01% 1876
2024
Q4 		$1.23M Buy
52,762
+9,302
+21% +$273K ﹤0.01% 1808
2024
Q3 		$1.28M Buy
43,460
+5,678
+15% +$158K ﹤0.01% 1789
2024
Q2 		$888K Buy
37,782
+13,125
+53% +$443K ﹤0.01% 1922
2024
Q1 		$935K Buy
+24,657
New +$714K ﹤0.01% 1893
2022
Q2 		– Sell
-467
Closed -$26.9K – 3132
2022
Q1 		$26.9K Sell
467
-339
-42% -$28.5K ﹤0.01% 3055
2021
Q4 		$96K Sell
806
-207
-20% -$32.7K ﹤0.01% 3058
2021
Q3 		$201K Sell
1,013
-48
-5% -$8.39K ﹤0.01% 2985
2021
Q2 		$185K Sell
1,061
-103
-9% -$18.7K ﹤0.01% 3149
2021
Q1 		$230K Sell
1,164
-1
-0.1% -$192 ﹤0.01% 2806
2020
Q4 		$229K Buy
1,165
+135
+13% +$28K ﹤0.01% 2695
2020
Q3 		$183K Hold
1,030
– – ﹤0.01% 2606
2020
Q2 		$236K Buy
1,030
+287
+39% +$54.7K ﹤0.01% 2413
2020
Q1 		$87K Buy
743
+47
+7% +$7.99K ﹤0.01% 2617
2019
Q4 		$133K Sell
696
-89
-11% -$17.5K ﹤0.01% 2722
2019
Q3 		$150K Buy
785
+4
+0.5% +$779 ﹤0.01% 2707
2019
Q2 		$134K Buy
+781
New +$135K ﹤0.01% 2814
2018
Q3 		– Sell
-550
Closed -$145K – 3794
2018
Q2 		$145K Buy
+550
New +$135K ﹤0.01% 3314

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s SYRE Position: Q2 2026 in Review

Manulife (Manufacturers Life Insurance) reduced its Spyre Therapeutics (SYRE) stake by 7.4% in Q2 2026, selling an estimated $607K and leaving 104,516 shares worth $9.28M. The position accounts for 0.01% of the portfolio, ranked #925.

Manulife (Manufacturers Life Insurance) first reported a position in SYRE in Q2 2018 and has held it in 23 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Manulife (Manufacturers Life Insurance) held 104,516 shares of Spyre Therapeutics worth $9.28M as of Q2 2026.
  • Manulife (Manufacturers Life Insurance) sold 8,325 Spyre Therapeutics shares in Q2 2026, an estimated $607K.
  • Spyre Therapeutics made up 0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q2 2026, its #925 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in Spyre Therapeutics in Q2 2018 and has held it in 23 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q2 2026, filed 14 Aug 2026.